Blood Pressure Vaccine Lengthens Rat Lives

A DNA-based vaccine gave rats six months of protection against high blood pressure as well as healthier hearts. Christopher Intagliata reports

Illustration of a Bohr atom model spinning around the words Science Quickly with various science and medicine related icons around the text

Join Our Community of Science Lovers!

Some 70 million American adults have high blood pressure. Three quarters of them rely on medication to keep the condition in check. But you've got to remember to actually take the daily dose. Now researchers have devised a longer-lasting alternative: a vaccine to lower blood pressure…for rats, at least.

Scientists jabbed hypertensive rats with three doses of the formulation. It's a DNA vaccine—containing DNA fragments from angiotensin II—a hormone that boosts blood pressure, as well as fragments from hepatitis B, to guarantee the immune system’s attention. Cells suck up the vaccine's DNA, and start pumping out the proteins the DNA codes for. When the host’s defenses gets a whiff of the proteins, it reacts. It really revs up against the hepatitis B fragments. And while it’s at it, it starts taking out some angiotensin II as well.  

The result is a reduction in angiotensin II's usual blood pressure raising effects—similar to what blood pressure meds like Benicar do. Less angiotensin II means more relaxed blood vessels, and a drop in pressure. That effect lasted six months in the vaccinated rats, and lengthened their lifespan by eight weeks. Necropsies on the vaccinated rats revealed healthier heart tissue than normally found with high blood pressure, and no damage to their kidneys or livers. The results are in the journal Hypertension. [Hiroshi Koriyama et al, Long-Term Reduction of High Blood Pressure by Angiotensin II DNA Vaccine in Spontaneously Hypertensive Rats]


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


Other blood pressure vaccines have been tried, unsuccessfully. But this novel DNA-based vaccine could induce a longer-lasting effect. And the hope of twice-yearly shots instead of daily pills.

—Christopher Intagliata 

[The above text is a transcript of this podcast.]

It’s Time to Stand Up for Science

If you enjoyed this article, I’d like to ask for your support. Scientific American has served as an advocate for science and industry for 180 years, and right now may be the most critical moment in that two-century history.

I’ve been a Scientific American subscriber since I was 12 years old, and it helped shape the way I look at the world. SciAm always educates and delights me, and inspires a sense of awe for our vast, beautiful universe. I hope it does that for you, too.

If you subscribe to Scientific American, you help ensure that our coverage is centered on meaningful research and discovery; that we have the resources to report on the decisions that threaten labs across the U.S.; and that we support both budding and working scientists at a time when the value of science itself too often goes unrecognized.

In return, you get essential news, captivating podcasts, brilliant infographics, can't-miss newsletters, must-watch videos, challenging games, and the science world's best writing and reporting. You can even gift someone a subscription.

There has never been a more important time for us to stand up and show why science matters. I hope you’ll support us in that mission.

Thank you,

David M. Ewalt, Editor in Chief, Scientific American

Subscribe